Gilead is teaming up with Vir on solid tumor cancer drugs in a deal worth up to $1.9 billion
Vir Biotechnology will receive $90 million upfront and could earn up to $1.74 billion in later milestone payments
We haven't written up this one. Quartz has the full story — the link below goes straight to it.